Last reviewed · How we verify
Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery
The purpose of this study is to evaluate the effects of enoxaparin on bleeding and venous blood clots in patients with hip fracture surgery.
Details
| Lead sponsor | Sanofi |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 54 |
| Start date | 2006-07 |
| Completion | 2007-03 |
Conditions
- Hip Fractures
Interventions
- enoxaparin (XRP4563)
Primary outcomes
- bleeding events — 28 days
Countries
Japan